HB Wealth Management LLC Makes New $156,000 Investment in MiMedx Group, Inc $MDXG

HB Wealth Management LLC purchased a new position in MiMedx Group, Inc (NASDAQ:MDXG) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 25,521 shares of the company’s stock, valued at approximately $156,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. OneDigital Investment Advisors LLC grew its stake in shares of MiMedx Group by 3.9% in the 1st quarter. OneDigital Investment Advisors LLC now owns 55,157 shares of the company’s stock worth $419,000 after buying an additional 2,056 shares during the last quarter. Rhumbline Advisers grew its stake in shares of MiMedx Group by 1.4% in the 1st quarter. Rhumbline Advisers now owns 177,156 shares of the company’s stock worth $1,346,000 after buying an additional 2,436 shares during the last quarter. Isthmus Partners LLC grew its stake in shares of MiMedx Group by 1.1% in the 1st quarter. Isthmus Partners LLC now owns 310,262 shares of the company’s stock worth $2,358,000 after buying an additional 3,455 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of MiMedx Group by 5.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 73,518 shares of the company’s stock worth $559,000 after buying an additional 4,049 shares during the last quarter. Finally, AQR Capital Management LLC grew its stake in shares of MiMedx Group by 42.6% in the 1st quarter. AQR Capital Management LLC now owns 14,374 shares of the company’s stock worth $109,000 after buying an additional 4,296 shares during the last quarter. Hedge funds and other institutional investors own 79.15% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on MDXG shares. Cantor Fitzgerald upped their price target on MiMedx Group from $11.00 to $12.00 and gave the stock an “overweight” rating in a research note on Thursday, July 31st. Wall Street Zen upgraded MiMedx Group from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 2nd. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of MiMedx Group in a research report on Saturday, September 27th. One analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, MiMedx Group presently has an average rating of “Moderate Buy” and an average price target of $12.00.

MiMedx Group Trading Down 0.7%

Shares of MDXG stock opened at $7.26 on Wednesday. MiMedx Group, Inc has a 52-week low of $5.47 and a 52-week high of $10.14. The company has a debt-to-equity ratio of 0.08, a quick ratio of 3.90 and a current ratio of 4.39. The firm has a market capitalization of $1.07 billion, a PE ratio of 34.57 and a beta of 1.73. The stock has a fifty day simple moving average of $7.08 and a two-hundred day simple moving average of $6.85.

MiMedx Group (NASDAQ:MDXG) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.04. The business had revenue of $98.61 million during the quarter, compared to analyst estimates of $90.79 million. MiMedx Group had a return on equity of 23.03% and a net margin of 8.84%. On average, analysts predict that MiMedx Group, Inc will post 0.3 EPS for the current fiscal year.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.